News

Bioelectronic medicine vendors and researchers pursuing novel applications of sensing and stimulation technology have much to gain the cardiac device industry. In the future, we expect advances in cardiac devices to be intertwined with advances in neuromodulation. One area that is ripe for development involves the integration of implanted devices with human tissue. Neural engineers developing next-…

Manufacturers of implanted and noninvasive peripheral nerve stimulation systems see tremendous opportunity in the years ahead for treating a wide variety of neurological conditions that are not well served pharmaceutical therapies. But the wide-open market opportunity for PNS is tempered obtaining reimbursement for their products. Perhaps the greatest obstacle confronting PNS vendors is the relatively low levels of payment offered and Medicaid Services, which often sets the standard for private payers.

The bioelectronic medicine market for treating sleep disorders using hypoglossal nerve stimulation is rapidly becoming more competitive as new vendors emerge and existing players report progress. While Inspire Medical currently has the U.S. market to itself, Nyxoah has begun to compete in Europe and expects to gain FDA approval soon. Earlier this month, Nyxoah announced that its DREAM pivotal study in the U.S.

Executives and entrepreneurs from several neurotechnology firms participated in the 2024 LSI Emerging Medtech Conference in Dana Point earlier this month. The conference featured numerous sessions with medtech investors and strategics offering insights on commercialization issues. Among the neuromodulation firms making presentations at the event were Bionic Vision Technologies, BackStop Neural, Neu…

Over the last few years, media attention to advances in brain-computer interface technology has spiked considerably, in large part because of announcements firm, Neuralink. Make no mistake, Neuralink’s progress has been noteworthy, particularly reports from the company’s first patient, who was able to move a computer cursor and play computer games using the company’s implanted device. But putting a…

Future advances in implantable neurotechnology devices will depend heavily on developments in materials science. In particular, soft, thin, flexible materials that conform to neural tissue and conduct electricity are highly desirable for brain implants. Researchers at a number of institutions have recently reported progress with two such materials: EGNITE and PEDOT: PSS. A study published in Nature…

The neurotechnology market opportunity for treating Parkinson’s disease has been dominated by deep-brain stimulation systems. But in recent months, some new neurotech therapies exploiting other forms of neuromodulation have emerged from two research teams in Asia. A team of researchers from Japan has developed a novel neuromodulation approach that features gait-combined closed-loop transcranial electrical stimulation.

The potential market for treating diabetes has proven to be an elusive, though alluring target for bioelectronic medicine vendors. The dearth of effective therapies for advanced type 2 diabetes represents one of the greatest unmet medical needs of our generation. Several bioelectronic medicine startups, including MetaCure, Cyberonics (now LivaNova), EnteroMedics (now ReShape LifeSciences), Intrapac…

Tom Oxley to Keynote Seventh Annual Bioelectronic Medicine Forum in NYC Neurotech Reports, the publisher of the Neurotech Business Report and BioElectRx Business Report newsletters, announced that the Tom Oxley, the CEO of Synchron Inc., will keynote the Seventh Annual Bioelectronic Medicine Forum. Synchron’s internationally acclaimed stentrode device can record brain activity from within a blood vessel.

In the 20-plus years that we’ve been publishing this newsletter, we’ve devoted considerable coverage to emerging and established neurotech firms, and the entrepreneurs and investors who’ve made those concerns successful. Where we may not have devoted enough ink—or shall we say pixels, since we ceased mailing printed copies in 2023—is to the scientific and clinical investigators who have moved the neurotechnology field forward.